Stocks · News reference
Filed: 2026-08-06 AccNo: 0001193125-26-336772 Size: 407 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Citizens analyst Silvan Turkcan reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Market Outperform and maintains $30 price target.
Read original at benzingaEvercore ISI Group analyst Jonathan Miller upgrades Intellia Therapeutics (NASDAQ:NTLA) from In-Line to Outperform and raises the price target from $16 to $24.
Read original at benzingaIntellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.79) by 1.27 percent. This is a 18.37 percent increase over losses of $(0.98) per
Read original at benzinga